Previous Close | 7.14 |
Open | 7.30 |
Bid | 6.79 x 1000 |
Ask | 6.81 x 800 |
Day's Range | 6.58 - 7.33 |
52 Week Range | 1.05 - 11.59 |
Volume | |
Avg. Volume | 4,087,914 |
Market Cap | 409.585M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.54 |
Earnings Date | Aug 09, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.95 |
Subscribe to Yahoo Finance Plus to view Fair Value for AVDL
Received tentative approval for LUMRYZ™ (sodium oxybate) extended-release for oral suspension from FDA on July 18Advancing key activities to potentially accelerate final approval and shorten launch window of LUMRYZExtended cash runway to final FDA decisionManagement to host a conference call today at 8:00 a.m. ET DUBLIN, Ireland, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today pro
The average of price targets set by Wall Street analysts indicates a potential upside of 105.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, August 9, 2022, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2022. To access the conference call, investors are invited to dial (833) 630-0586 (U.S.) or (412) 3